Oruka Therapeutics, Inc. (ORKA)

NASDAQ: ORKA · Real-Time Price · USD

105.35

+0.36 (0.34%)

At close: Nov 13, 2026, 4:00 PM EST

106.15

+0.80 (0.76%)

After-hours: Nov 13, 2026, 7:30 PM EST

Oruka Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Selling, General & Admin	29.37	21.41	14.25
Research & Development	153.74	100.64	81.01
Operating Expenses	183.11	122.05	95.26
Operating Income	-183.11	-122.05	-95.26
Interest Expense	-	-	-1.6
Interest & Investment Income	30.52	16.63	6.4
Other Non Operating Income (Expenses)	0.02	-0.01	0
EBT Excluding Unusual Items	-152.57	-105.43	-90.46
Other Unusual Items	-	-	-0.87
Pretax Income	-152.57	-105.43	-91.34
Net Income	-152.57	-105.43	-91.34
Preferred Dividends & Other Adjustments	-22.21	-21.12	-20.39
Net Income to Common	-130.37	-84.31	-70.95
Net Income Growth	-	-	-
Shares Outstanding (Basic)	61	46	17
Shares Outstanding (Diluted)	61	46	17
Shares Change	42.31%	171.69%	-
EPS (Basic)	-2.13	-1.85	-4.23
EPS (Diluted)	-2.13	-1.85	-4.23
EPS Growth	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Free Cash Flow	-123.86	-88.42	-63.3
Free Cash Flow Per Share	-2.03	-1.94	-3.77
EBITDA	-182.95	-121.97	-95.23
D&A For EBITDA	0.16	0.08	0.03
EBIT	-183.11	-122.05	-95.26

SEC Filings: 10-K · 10-Q